16.87
0.84%
0.14
Acadia Pharmaceuticals Inc stock is traded at $16.87, with a volume of 4.75M.
It is up +0.84% in the last 24 hours and up +3.69% over the past month.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
See More
Previous Close:
$16.73
Open:
$16.51
24h Volume:
4.75M
Relative Volume:
3.22
Market Cap:
$2.81B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
-18.34
EPS:
-0.92
Net Cash Flow:
$80.53M
1W Performance:
-2.26%
1M Performance:
+3.69%
6M Performance:
+14.37%
1Y Performance:
-41.93%
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
16.87 | 2.81B | 890.53M | 30.57M | 80.53M | 0.18 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-10-24 | Resumed | Raymond James | Mkt Perform |
Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
Mar-12-24 | Reiterated | Needham | Buy |
Jan-30-24 | Initiated | Robert W. Baird | Outperform |
Jan-24-24 | Upgrade | Needham | Hold → Buy |
Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
Dec-13-23 | Initiated | Citigroup | Buy |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
Oct-17-23 | Initiated | UBS | Buy |
Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
Nov-01-22 | Initiated | Loop Capital | Hold |
Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-23-21 | Resumed | Needham | Hold |
Jun-10-21 | Initiated | Berenberg | Hold |
Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
Mar-09-21 | Downgrade | Stifel | Buy → Hold |
Dec-16-20 | Initiated | Mizuho | Buy |
Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
Aug-25-20 | Initiated | Raymond James | Outperform |
Aug-20-20 | Initiated | Morgan Stanley | Overweight |
Jul-07-20 | Upgrade | Stifel | Hold → Buy |
Apr-16-20 | Initiated | Jefferies | Buy |
Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
Mar-06-20 | Initiated | Citigroup | Buy |
Dec-16-19 | Initiated | Guggenheim | Buy |
Oct-24-19 | Initiated | Oppenheimer | Perform |
Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
Jul-23-19 | Reiterated | Needham | Buy |
Dec-10-18 | Initiated | Canaccord Genuity | Hold |
Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
Aug-09-18 | Reiterated | Stifel | Hold |
Aug-07-18 | Initiated | Stifel | Hold |
Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
Acadia Pharmaceuticals to Present at J.P. Morgan Healthcare Conference: Pioneering CNS Treatment Innovations - StockTitan
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 2.9%What's Next? - MarketBeat
Schizophrenia Market Predicted to See Upsurge Through 2034, - openPR
State Street Corp Acquires 173,084 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals Awards Stock Options, RSUs to New Hires in Neuroscience Expansion - StockTitan
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Position Reduced by Fmr LLC - MarketBeat
ACADIA Pharmaceuticals' SWOT analysis: stock outlook amid Daybue challenges - Investing.com
Acadia closes on $150M FDA voucher sale - MSN
Y Intercept Hong Kong Ltd Sells 39,245 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Neo Ivy Capital Management Reduces Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals Secures $150M Windfall from Priority Review Voucher Sale, Boosts R&D Pipeline - StockTitan
Pharma Pulse 12/10/24: Did Industry Fumble the DSCSA Deadline? Operationalizing Bispecifics Resources & more - Pharmaceutical Executive
Postoperative Pain Market: Market Outlook, Epidemiology Insights, Therapies, Key Companies in the Market | ACADIA Pharmaceuticals, Adynxx, Apsen Farmaceutica, Arthritis Innovation Corporation, Cali - Barchart
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer - BioSpace
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead - FiercePharma
Acadia Buys Saniona Tremor Drug - San Diego Business Journal
Walleye Capital LLC Has $628,000 Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Brokerages Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56 - MarketBeat
Pharma Pulse 12/5/24: Gaps in Publicly Funded Non-Inferiority Clinical Trials, Are GLP-1s Eliminating the Need for Bariatric Surgery? & more - Pharmaceutical Executive
The Manufacturers Life Insurance Company Sells 48,809 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Jacobs Levy Equity Management Inc. Sells 143,688 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
BNP Paribas Financial Markets Boosts Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options - MSN
Ryan Reynolds' Latest Film: 'More To Parkinson's' 08/19/2024 - MediaPost Communications
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Erste Asset Management GmbH Makes New $3.80 Million Investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Significant Growth in Short Interest - MarketBeat
The week in deals: Acadia taps Saniona for GABRA3 modulator, and more - BioCentury
Rockefeller Capital Management L.P. Has $17.53 Million Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Edgestream Partners L.P. Raises Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
37,683 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Purchased by Intech Investment Management LLC - MarketBeat
Zacks Research Has Strong Estimate for ACAD FY2024 Earnings - MarketBeat
Acadia signs licensing deal for essential tremor drug candidate - MSN
Fred Alger Management LLC Raises Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Fisher Asset Management LLC Acquires 31,980 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
ACADIA Pharmaceuticals' SWOT analysis: stock outlook mixed as DAYBUE launch faces hurdles - Investing.com India
Acadia signs deal with Saniona for SAN711 rights - The Pharma Letter
Saniona’s CEO: “The deal with Acadia is significant”BioStock - BioStock - Connecting Innovation and Capital
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET (NASDAQ:ACAD) - Seeking Alpha
Saniona Cash Worries Ease With Acadia Neuro Biobucks Pact - Citeline
ACAD Signs License Deal With Saniona for Rights to Neurology Drug - Yahoo Finance
Acadia licenses Saniona’s SAN711 for essential tremor in deal worth up to $610m - World Pharmaceutical Frontiers
Acadia snaps up an essential tremor drug after field’s summer setbacks - Endpoints News
Acadia signs agreement with Saniona to commercialise SAN711 - Pharmaceutical Technology
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 - BioSpace
Acadia secures Saniona's experimental tremor drug in $600M deal - FirstWord Pharma
Saniona signs license agreement with Acadia Pharmaceuticals for SAN711 - Marketscreener.com
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for San711 - Marketscreener.com
Acadia licenses novel treatment for essential tremor By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711 - MarketWatch
Acadia nabs rights to Saniona's tremor asset in $582M biobucks deal - Fierce Biotech
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):